Molbio Diagnostics IPO Subscribed 1.22 Times on Day 2

Molbio Diagnostics' initial public offering (IPO) was subscribed 1.22 times by the end of Day 2 on Tuesday, August 11, 2026. The Rs 939.70-crore public issue opened on August 10 and will close on August 12.

The employee portion received the strongest response and was subscribed 2.69 times on Day 2, compared with 2.12 times on the opening day. This indicates a high level of confidence among the company's employees in its future prospects.

The non-institutional investor (NII) category was booked 1.37 times, rising from 0.73 times on Day 1. Within this segment, the small NII portion was subscribed 1.67 times, while the big NII portion attracted 1.22 times bids. Retail investors also showed improved interest, with the retail individual investor portion subscribed 1.26 times, against 0.77 times on the first day.

The qualified institutional buyer (QIB) category remained subscribed 1.00 time, unchanged from Day 1. Overall subscription improved from 0.83 times on Monday to 1.22 times on Tuesday.

The IPO price band has been fixed at Rs 768 to Rs 807 per equity share. Investors can apply for a minimum lot of 18 shares. At the upper end of the price band, one lot will cost Rs 14,526. Of the total offer, 50 percent is reserved for QIBs, 35 percent for retail investors and 15 percent for NIIs.

Molbio Diagnostics develops rapid and affordable testing products for infectious and non-communicable diseases. Its main product, Truenat, is a portable, battery-powered PCR testing platform that can provide results within an hour. The platform is designed for use at the point of care, including areas with limited laboratory facilities.

Through its wholly owned subsidiary Bigtec Labs, the company carries out research and develops diagnostic technology. The company's products have the potential to make a significant impact in the healthcare sector, particularly in rural and underserved areas.

The strong response to the IPO is a positive sign for the company, which plans to use the funds raised to expand its operations and further develop its products. The shares are proposed to be listed on the BSE and NSE.

Investors can apply for the IPO through the ASBA facility offered by banks or through supported stockbroking applications using UPI. Applicants should check the price, business risks, financial performance and subscription data before making any investment decision.

The success of the IPO will depend on various factors, including the company's financial performance, industry trends, and overall market conditions. However, with its strong product portfolio and growing demand, Molbio Diagnostics is well-positioned for future growth.

In conclusion, the strong response to Molbio Diagnostics' IPO is a positive sign for the company and the healthcare sector as a whole. With its innovative products and growing demand, the company has the potential to make a significant impact in the years to come.